Form 4: Teladoc Health Executive Kelly Bliss Reports Routine Stock Transactions, Including Tax-Related Sale

Teladoc Health's President of U.S. Group Health, Kelly Bliss, reported the acquisition of common stock through vesting of performance and restricted stock units, alongside a sale of shares to cover tax obligations.

Summary

• Kelly Bliss, President, U.S. Group Health at Teladoc Health, Inc. (TDOC), reported transactions involving company common stock as part of her equity compensation.
• On May 30, 2025, Ms. Bliss acquired a total of 9,535 shares of common stock through the conversion of performance stock units (1,189 shares) and restricted stock units (3,488 shares and 4,858 shares).
• Following these acquisitions, Ms. Bliss's direct beneficial ownership of common stock increased to 54,919 shares before the subsequent sale.
• On June 2, 2025, Ms. Bliss sold 4,653 shares of Teladoc Health common stock at a price of $6.86 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the vesting of her performance stock unit and restricted stock unit awards.
• After all reported transactions, Ms. Bliss's direct beneficial ownership of Teladoc Health common stock stands at 50,266 shares.
• Ms. Bliss still holds significant unvested equity, including 3,564 Performance Stock Units, 10,464 Restricted Stock Units, and 34,009 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The document reports routine insider transactions related to equity compensation. The sale of shares is for tax purposes, which is a common and expected event, not indicative of negative sentiment towards the company. The continued holding of a significant number of shares and unvested units by the executive is a positive alignment of interests.

Positives

• The acquisition of shares indicates the vesting of previously granted equity awards, which is a normal and expected part of executive compensation and retention strategies.
• The executive continues to hold a significant number of shares (50,266) and substantial unvested equity awards (48,037 units), aligning her interests with those of shareholders.

Negatives

• A sale of shares by an insider, even for tax purposes, can sometimes be perceived negatively by the market, although it is a common and routine practice for covering tax liabilities on vested equity.
• The sale price of $6.86 per share is noted.

Future Outlook

The document does not provide a future outlook for the company's performance or strategic direction. It only details past and current insider stock transactions and remaining unvested equity awards.

Industry Context

This Form 4 filing is specific to an individual executive's equity compensation and does not provide broader industry context or trends. It reflects routine executive compensation practices within the healthcare technology sector.

Comparison to Industry Standards

• This document is a standard insider trading report (Form 4) and does not contain information suitable for comparison to industry-specific operational or financial benchmarks.
• The transactions reported, specifically the vesting of equity awards and subsequent sale of shares to cover tax liabilities, are typical and common practices for executives across various industries receiving equity-based compensation.

Stakeholder Impact

• Shareholders: Provides transparency on executive stock ownership and transactions, which can influence investor perception of management's alignment with shareholder interests. The sale for tax purposes is a common practice and generally not a cause for concern.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued vesting of remaining Performance Stock Units and Restricted Stock Units according to their respective schedules.

Key Dates

Recommendation

Keywords

Teladoc Health, TDOC, Form 4, Insider Trading, Stock Transaction, Equity Compensation, Restricted Stock Units, Performance Stock Units, Executive Compensation, Kelly Bliss